Contribution of Radiotherapy to Function Preservation and Cancer Outcome in Primary Treatment of Nasopharyngeal Carcinoma

2003 ◽  
Vol 27 (7) ◽  
pp. 838-843 ◽  
Author(s):  
Anne W.M. Lee
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Treatment ◽  
Function Preservation ◽  
Cancer Outcome

scholarly journals Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy

2019 ◽  
Vol 39 (5) ◽  
Author(s):  
Guangying Zhang ◽  
Kun Zhang ◽  
Chao Li ◽  
Yanyan Li ◽  
Zhanzhan Li ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Serum Proteins ◽  
Sequence Similarity ◽  
Predictive Biomarkers ◽  
Primary Treatment ◽  
Label Free ◽  
Discrimination Ability ◽  
Serum Proteomics ◽  
High Discrimination ◽  
Southern University

Abstract Radiotherapy is the primary treatment option for nasopharyngeal carcinoma (NPC). Local recurrence and metastasis caused by radioresistance become a bottleneck of curative effect for patients with NPC. Currently, serum predictive biomarkers of radioresistance are scare. We enrolled NPC patients, who underwent radiotherapy in the Department of Oncology, Xiangya Hospital, Central Southern University, and analyzed the serum proteins profiles in NPC patients using with quantitative label-free proteomics using ultra-definition MS. Patients were divided into those who were radioresistant and radiosensitive by the overall reduction (≤50% or >50%, respectively) in tumor extent. The MS/MS spectrum database search identified 911 proteins and 809 proteins are quantitatable. Eight proteins significantly up-regulated and 12 serum proteins were significantly down-regulated in the radioresistance group compared with radiosensitivity group (P<0.05). Finally, five proteins entered the optimal models, including secreted protein acidic and cysteine rich (SPARC) (P=0.032), serpin family D member 1S (ERPIND1) (P=0.040), complement C4B (C4B) (P=0.017), peptidylprolyl Isomerase B (PPIB) (P=0.042), and family with sequence similarity 173 member A (FAM173A) (P=0.017). In all patient, the area under the curves (AUC) for SPARC, SERPIND, C4B, PPIB, and FAM173A were 0.716 (95% CI: 0.574–0.881), 0.697 (95% CI: 0.837–0.858), 0.686 (95% CI: 0.522–0.850), 0.668 (95% CI: 0.502–0.834) and 0.657 (95% CI: 0.512–0.825), respectively. The AUC of five selected proteins was 0.968 (95% CI: 0.918–1.000) with the sensitivity of 0.941 and the specificity of 0.926. Our result indicated that a panel including five serum protein (SPARC SERPIND1 C4B PPIB FAM173A) based on serum proteomics provided a high discrimination ability for radiotherapy effects in NPC patients. Studies with larger sample size and longer follow-up outcome are required.

scholarly journals EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma

Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769597 ◽  
Author(s):  
Mei Tang ◽  
Ru-yan Liu ◽  
Cong Zhou ◽  
Meng-zhen Yuan ◽  
Dong-ming Wu ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Molecular Mechanisms ◽  
Radiation Sensitivity ◽  
Primary Treatment ◽  
Phase Cell ◽  
Clinical Samples ◽  
Survival Times ◽  
Normal Tissues ◽  
Cycle Arrest ◽  
Epithelial Membrane Protein 2

Although radiation therapy is the primary treatment for nasopharyngeal carcinoma, radioresistance remains a major obstacle to successful treatment in many cases, and the exact underlying molecular mechanisms are still ill-defined. EMP2, epithelial membrane protein-2, was a recently identified potential oncogene involved in multiple biological processes including cell migration and cell proliferation. This study was to explore the potential relationship between EMP2 expression, nasopharyngeal carcinoma genesis, and radioresistance. EMP2 expression status in 98 nasopharyngeal carcinoma clinical samples was examined by immunohistochemical staining. As a result, most of the nasopharyngeal carcinoma tumor samples were weakly or negatively stained, while paired adjacent normal tissues were moderately or strongly stained. Moreover, patients with higher expression of EMP2 had significant longer survival times. EMP2 re-expression suppresses cell growth, induces S-phase cell cycle arrest, and promotes radiosensitivity and apoptosis in nasopharyngeal carcinoma cells. These results support that loss of EMP2 is common, and its re-expression may serve as an approach to enhance radiation sensitivity in nasopharyngeal carcinoma.

scholarly journals EP-1135 Effect of Primary Treatment on Neck Dissection Choice in Nasopharyngeal Carcinoma Regional Failure

2019 ◽  
Vol 133 ◽  
pp. S630-S631
Author(s):  
R. Sim ◽  
S. Mueller ◽  
G. Iyer ◽  
N.C. Tan ◽  
K.C. Soo ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Neck Dissection ◽  
Primary Treatment ◽  
Regional Failure

scholarly journals Fighter Pilots With Nasopharyngeal Carcinoma Successfully Returning to Flight After Radiotherapy: A Case Series

2019 ◽  
Vol 185 (3-4) ◽  
pp. e522-e525
Author(s):  
Shih-Ming Chen ◽  
Kuen-Tze Lin ◽  
Yang-Hong Dai ◽  
Kwo-Tsao Chiang ◽  
Shih-Yu Lee
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Tumor Regression ◽  
Locally Advanced ◽  
Case Series ◽  
Pure Tone Audiometry ◽  
Primary Treatment ◽  
Concurrent Chemotherapy ◽  
Hearing Function ◽  
Average Improvement ◽  
Physical Examinations

Abstract For nasopharyngeal carcinoma (NPC), radiotherapy is the primary treatment. However, complications occur after radiation to the nasopharynx, which could potentially affect the flying safety. Four fighter pilots with NPC were reported. With early to locally advanced NPC, they received radiotherapy with or without concurrent chemotherapy. The prescribed radiation dose was 70 Gy to the primary tumor over the nasopharynx. Before treatment, all patients presented with various degrees of hearing loss on pure tone audiometry (main frequencies of 20–45 dB at 3–4.5 kHz for affected ears). After the full course of radiotherapy, tumor regression was noticed during months to years of follow-ups. The follow-up audiometry evaluation showed gradually recovered hearing function (average improvement of 5 dB at pretreatment frequencies) in all pilots. They then returned back to the flight line on annual waiver points. Here, we conclude that fighter pilots with NPC could successfully return to the flight line after radiotherapy. However, detailed physical examinations and confirmation of adaptation to flying condition are warranted.

scholarly journals Radiotherapy dose escalation in the primary treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis

2019 ◽  
Vol 3 ◽  
pp. 1-1 ◽  
Author(s):  
Lester Bryan A. Co ◽  
Ryan Anthony F. Agas ◽  
JC Kennetth M. Jacinto ◽  
Kelvin Ken L. Yu ◽  
Michael A. Mejia ◽  
...  
Keyword(s):  
Systematic Review ◽  
Nasopharyngeal Carcinoma ◽  
Dose Escalation ◽  
Meta Analysis ◽  
Primary Treatment ◽  
Radiotherapy Dose

scholarly journals Primary Treatment Results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e63706 ◽  
Author(s):  
Maarten A. Wildeman ◽  
Renske Fles ◽  
Camelia Herdini ◽  
Rai S. Indrasari ◽  
Andrew D. Vincent ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Primary Treatment ◽  
Treatment Results

scholarly journals The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Yi-Jun Hua ◽  
Yan-Feng Ou-Yang ◽  
Xiong Zou ◽  
Le Xia ◽  
Dong-Hua Luo ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Distant Metastasis ◽  
Healthcare Providers ◽  
Intensity Modulated Radiotherapy ◽  
Progression Free Survival ◽  
Primary Treatment ◽  
Free Survival ◽  
Intensity Modulated ◽  
Distant Failure ◽  
Prolonged Duration

PurposeRadiotherapy is the most important primary treatment for patients with nasopharyngeal carcinoma. Generally, the treatment duration of radiotherapy takes six or six and half weeks with 30 to 33 fractions. The current study was conducted to evaluate the association between prognosis and the duration of radiotherapy in nasopharyngeal carcinoma patients.MethodsPatients with primary nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy, with or without induction chemotherapy between January, 2008 and December, 2013 at a single institution were retrospectively reviewed.ResultsIn total, 1292 patients were included. At a median follow-up of 71.0 months (range 2.0–126.0 months), locoregional recurrence, distant failure and death were observed in 8.8%, 12.2% and 15.6% of all patients, respectively. Estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in patients with radiation ≤ 7 weeks versus patients with radiation &gt;7 weeks were: 93.2% versus 87.0% (P &lt; 0.001), 89.4% versus 84.4% (P = 0.016), 79.8% versus 70.6% (P &lt; 0.001) and 87.2% versus 78.4% (P &lt; 0.001), respectively.ConclusionsProlonged duration of radiotherapy with a significantly higher risk of distant metastasis and death in nasopharyngeal carcinoma patients. Understanding this point, healthcare providers should make efforts to avoid prolonged duration of radiotherapy to minimize the risk of treatment failure.

Capecitabine-based chemotherapy versus primary treatment for patients with advanced stages of undifferentiated nasopharyngeal carcinoma (UCNT): Preliminary results of a phase II study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17049-e17049
Author(s):  
H. Djedi ◽  
K. Bouzid
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Cardiac Toxicity ◽  
Treatment Plan ◽  
Objective Response ◽  
Rest Period ◽  
Complete Response ◽  
Primary Treatment ◽  
Hand Foot Syndrome ◽  
Advanced Stages ◽  
Undifferentiated Nasopharyngeal Carcinoma

e17049 Background: The combination of cisplatin and 5-fluorouracil (5-FU) is considered to be the standard treatment in induction chemotherapy for patients with undifferentiated nasopharyngeal carcinoma (UCNT). Capecitabine is an oral fluoropyrimidine. The aim of our study is to evaluate overall response and toxicity of this drug as a primary chemotherapy based-regimen for patients with advanced stages of UCNT. Methods: From January 2008 through December 2008, 34 chemo-naives patients with UCNT were included, mean age: 45.2 years (range 14–61 years), 12F/22M. One patient was stage IIB, nine patients stage III, 17 patients stage IVA, five patients stage IVB, and two patients stage IVC. All patients received at least 3 to 4 courses of neoadjuvant chemotherapy. The treatment plan included cisplatin at dose of 75 mg/m2 on D1 every 21 days, followed by capecitabine at a dose of 1,000 mg/m2 twice daily from D2 to D 15, with a 1-week rest period. Five patients received this scheme plus docetaxel at a dose of 75 mg/m2 on D1 with prophylactic granulocyte colony stimulating factors: lenograstim or filgrastim. All patients had a clinical evaluation of objective response and toxicity before at each cure . A CT scan was done at the end of treatment before radiotherapy. Results: After a total of 114 courses, all patients (34 pts) were evaluable for toxicity and 26 patients were evaluable for response (8 pts have not yet achieved their treatment). A clinical benefit was obtained for all patients since the first cure of chemotherapy. The overall objective response (CR+PR) was achieved in 96% of cases (25/26pts ), one patient had a stable disease. One of the two patients with stage IVC had a complete response on hepatic metastasis after 3 cures. Grade 3/4 toxicity included: diarrhea 5.2%, nausea/vomiting: 9.6%, hand-foot syndrome 3.5%, febrile neutropenia 4.3%, cardiac toxicity: 0.8%, thrombocytopenia 1.75%. Chemotherapy was interrupted for one patient after only one cure because of the cardiac toxicity. Conclusions: Capecitabine based chemotherapy is a safety and an effective regimen in patients with UCNT. However a longer follow-up is needed to confirm the benefit on disease-free survive (DFS) and overall survivor. No significant financial relationships to disclose.

An Established Epithelial Cell Line (NPC/HK1) from a Nasopharyngeal Carcinoma - II. A Sem Study

1982 ◽  
Vol 40 ◽  
pp. 224-225
Author(s):  
Li C.L. ◽  
Chew E.C. ◽  
Huang D.P. ◽  
Ho H.C. ◽  
Mak L.S. ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Epithelial Cell ◽  
Surface Morphology ◽  
Cell Line ◽  
Epithelial Cell Line ◽  
Present Communication ◽  
Cells In Culture ◽  
Sem Study ◽  
Well Differentiated

An epithelial cell line, NPC/HK1, has recently been successfully established from a nasopharyngeal carcinoma of the moderately to well differentiated squamous type. The present communication reports on the surface morphology of the NPC/HK1 cells in culture.

Studies of Epstein-Barr Virus Antigens Using Immunoperoxidase and Immunofluorescence Techniques

1975 ◽  
Vol 33 ◽  
pp. 342-343
Author(s):  
R. Stephens ◽  
K. Traul ◽  
D. Woolf ◽  
P. Gaudreau
Keyword(s):  
Electron Microscopy ◽  
Nasopharyngeal Carcinoma ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
If Technique ◽  
Infected Cells ◽  
Virus Antigens ◽  
Epstein Barr ◽  
Virus Capsid Antigen ◽  
Antigen Reactivity

A number of antigens have been found associated with persistent EBV infections of lymphoblastoid cells. Identification and localization of these antigens were principally by immunofluorescence (IF) techniques using sera from patients with nasopharyngeal carcinoma (NPC), Burkitt lymphoma (BL), and infectious mononucleosis (IM). Our study was mainly with three of the EBV related antigens, a) virus capsid antigen (VCA), b) membrane antigen (MA), and c) early antigens (EA) using immunoperoxidase (IP) techniques with electron microscopy (EM) to elucidate the sites of reactivity with EBV and EBV infected cells.Prior to labeling with horseradish peroxidase (HRP), sera from NPC, IM, and BL cases were characterized for various reactivities by the indirect IF technique. Modifications of the direct IP procedure described by Shabo and the indirect IP procedure of Leduc were made to enhance penetration of the cells and preservation of antigen reactivity.

Sign in / Sign up

Export Citation Format

Share Document